Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center

Clinical Genitourinary Cancer

Volumn 14, Issue 4, 2016, Pages e299-e305

  Muralidhar, Vinayak ^a   Regan, Meredith M ^b   Werner, Lillian ^b   Nakabayashi, Mari ^b   Evan, Carolyn P ^b   Bellmunt, Joaquim ^b   Choueiri, Toni K ^b   Elfiky, Aymen A ^b   Harshman, Lauren C ^b   McKay, Rana R ^b   Pomerantz, Mark M ^b   Sweeney, Christopher J ^b   Taplin, Mary Ellen ^b   Kantoff, Philip W ^b   Nguyen, Paul L ^c  

^a HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ADT; Discontinuation; Side effects; Toxicity

Indexed keywords

GONADORELIN AGONIST; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN;

ADULT; ADULT COMORBIDITY EVALUATION 27; AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CENTER; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DRUG TOLERABILITY; FATIGUE; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SEXUAL DYSFUNCTION; SHORT COURSE THERAPY; SIDE EFFECT; TERTIARY HEALTH CARE; TREATMENT DURATION; CANCER GRADING; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; TERTIARY CARE CENTER; TREATMENT OUTCOME; TRENDS;

ANDROGEN ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; NEOPLASM GRADING; PRACTICE PATTERNS, PHYSICIANS'; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84953455439     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2015.12.008     Document Type: Article

References (22)

1. 1 NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer. 2015. Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed January 3, 2016.
2. 2 Bolla, M., de Reijke, T.M., Van Tienhoven, G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360 (2009), 2516–2527.
3. 3 Horwitz, E.M., Bae, K., Hanks, G.E., et al. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26 (2008), 2497–2504.
4. 4 NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer. 2009. Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf Accessed January 3, 2016.
5. 5 Nguyen, P.L., Alibhai, S.M., Basaria, S., et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67 (2015), 825–836.
6. 6 Efstathiou, J.A., Bae, K., Shipley, W.U., et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54 (2008), 816–823.
7. 7 Nanda, A., Chen, M.H., Braccioforte, M.H., Moran, B.J., D'Amico, A.V., Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302 (2009), 866–873.
8. 8 Alibhai, S.M., Duong-Hua, M., Sutradhar, R., et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 27 (2009), 3452–3458.
9. 9 D'Amico, A.V., Denham, J.W., Crook, J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25 (2007), 2420–2425.
10. 10 Oh, W.K., Hayes, J., Evan, C., et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer 5 (2006), 61–66.
11. 11 Kallogjeri, D., Piccirillo, J.F., Spitznagel, E.L. Jr., Steyerberg, E.W., Comparison of scoring methods for ACE-27: simpler is better. J Geriatr Oncol 3 (2012), 238–245.
12. 12 Nabid, A., Carrier, N., Martin, A.-G., et al. Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized trial. J Clin Oncol, 31(suppl), 2013 abstract LBA4510.
13. 13 Joniau, S., Briganti, A., Gontero, P., et al. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur Urol 67 (2015), 157–164.
14. 14 Spahn, M., Joniau, S., Gontero, P., et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 58 (2010), 1–11.
15. 15 Walz, J., Joniau, S., Chun, F.K., et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 107 (2011), 765–770.
16. 16 Lee, M., Jim, H.S., Fishman, M., et al. Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Psychooncology 24 (2015), 472–477.
17. 17 Ziehr, D.R., Chen, M.H., Zhang, D., et al. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int 116 (2015), 358–365.
18. 18 D'Amico, A.V., Chen, M.H., Renshaw, A.A., Loffredo, M., Kantoff, P.W., Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299 (2008), 289–295.
19. 19 Nguyen, P.L., Je, Y., Schutz, F.A., et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306 (2011), 2359–2366.
20. 20 Muralidhar, V., Dinh, K.T., Mahal, B.A., et al. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol 33 (2015), e19–e25.
21. 21 Gonzalez, B.D., Jim, H.S., Booth-Jones, M., et al. Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol 33 (2015), 2021–2027.
22. 22 DiBlasio, C.J., Malcolm, J.B., Derweesh, I.H., et al. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. BJU Int 102 (2008), 39–43.